

Resource Summary Report

Generated by T1D on Aug 1, 2026

BD Biosciences: LSR II Flow Cytometer

RRID:SCR_002159

Type: Tool

Proper Citation

BD Biosciences: LSR II Flow Cytometer (RRID:SCR_002159)

Resource Information

URL: <https://www.bd.com/resource.aspx?IDX=17868>

Proper Citation: BD Biosciences: LSR II Flow Cytometer (RRID:SCR_002159)

Description: Benchtop high-performance cell sorter with multiple laser, detector and fluorescence options. Allows detection of 12 parameters (10 color conjugates, forward and sideward scatter).

Abbreviations: LSR II Flow Cytometer

Resource Type: instrument resource

Keywords: flow cytometer, instrument, equipment, hardware

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Specification URL:

<https://drive.google.com/file/d/1iqsXa8XNCYWutCswBRYBWluHGag0IOSx/view?usp=drivesdk>

Resource Name: BD Biosciences: LSR II Flow Cytometer

Resource ID: SCR_002159

Alternate IDs: Model_Number_BD LSR II, SciRes_000152

Alternate URLs: <https://fccf.sitehost.iu.edu/pdf/BDLSRIIUserGuide.pdf>

Old URLs: http://www.rockefeller.edu/fcrc/pdf/BD_LSRII_Brochure_SJ-0142-00.pdf

Record Creation Time: 20220129T080211+0000

Record Last Update: 20260725T190516+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: LSR II Flow Cytometer.

No alerts have been found for BD Biosciences: LSR II Flow Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Jha V, et al. (2025) Substitution of Glutamic Acid at Position 71 of DR?1*04:01 and Collagen-Specific Tolerance Without Alloreactivity. Arthritis & rheumatology (Hoboken, N.J.), 77(5), 526.

Xue F, et al. (2025) CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. Cancers, 17(10).

Katkeviciute E, et al. (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. Cell reports, 44(3), 115357.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. Immunity, 58(7), 1742.

Kim AR, et al. (2025) Co-blockade of TGF? and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGF?RI Expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(15), 3306.

Wischnewski V, et al. (2025) The local microenvironment suppresses the synergy between irradiation and anti-PD1 therapy in breast-to-brain metastasis. Cell reports, 44(3), 115427.

Álvarez-Prado ÁF, et al. (2025) Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. Cell reports, 44(9), 116151.

Füchsl F, et al. (2024) High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. Nature communications, 15(1), 10520.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. Clinical and experimental immunology.

Rodriguez D, et al. (2024) Fractalkine isoforms differentially regulate microglia-mediated inflammation and enhance visual function in the diabetic retina. Journal of

neuroinflammation, 21(1), 42.

Nasser AM, et al. (2024) CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(14), 2996.

Rodriguez D, et al. (2024) Therapeutic Delivery of Soluble Fractalkine Ameliorates Vascular Dysfunction in the Diabetic Retina. *International journal of molecular sciences*, 25(3).

de Kivit S, et al. (2024) Immune suppression by human thymus-derived effector Tregs relies on glucose/lactate-fueled fatty acid synthesis. *Cell reports*, 43(9), 114681.

Huntington KE, et al. (2023) GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. *bioRxiv : the preprint server for biology*.

Chambers C, et al. (2023) SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. *Cancer research*, 83(7), 983.

Huntington KE, et al. (2023) GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. *International journal of molecular sciences*, 24(13).

Dressel N, et al. (2023) Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis. *Cancer research*, 83(17), 2858.

Pinho AG, et al. (2023) The Central Nervous System Source Modulates Microglia Function and Morphology In Vitro. *International journal of molecular sciences*, 24(9).

Darrah PA, et al. (2023) Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. *Cell host & microbe*, 31(6), 962.

Wu Y, et al. (2023) MicroRNA-223 limits murine hemogenic endothelial cell specification and myelopoiesis. *Developmental cell*, 58(14), 1237.